Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL [NASD]
Exelixis, Inc.
Index- P/E46.22 EPS (ttm)0.48 Insider Own1.10% Shs Outstand309.12M Perf Week-6.90%
Market Cap6.86B Forward P/E51.97 EPS next Y0.43 Insider Trans-9.04% Shs Float302.81M Perf Month10.31%
Income152.10M PEG1.00 EPS next Q0.05 Inst Own85.10% Short Float4.77% Perf Quarter1.61%
Sales957.80M P/S7.16 EPS this Y-53.80% Inst Trans0.24% Short Ratio6.04 Perf Half Y-11.37%
Book/sh5.99 P/B3.70 EPS next Y36.10% ROA14.10% Target Price30.83 Perf Year13.13%
Cash/sh3.84 P/C5.77 EPS next 5Y46.00% ROE15.80% 52W Range13.67 - 27.80 Perf YTD10.31%
Dividend- P/FCF18.42 EPS past 5Y22.50% ROI17.30% 52W High-20.36% Beta1.12
Dividend %- Quick Ratio6.90 Sales past 5Y107.60% Gross Margin96.10% 52W Low61.96% ATR0.96
Employees617 Current Ratio7.00 Sales Q/Q-14.90% Oper. Margin33.50% RSI (14)51.75 Volatility5.53% 3.95%
OptionableYes Debt/Eq0.00 EPS Q/Q-133.60% Profit Margin29.40% Rel Volume1.56 Prev Close21.32
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout0.00% Avg Volume2.39M Price22.14
Recom1.90 SMA200.73% SMA507.77% SMA200-2.12% Volume3,731,528 Change3.85%
Mar-04-20Initiated Barclays Overweight $26
Jan-13-20Initiated SunTrust Buy $31
Nov-13-19Initiated BofA/Merrill Buy $22
Mar-18-19Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-17-18Initiated Goldman Neutral $22
Sep-10-18Initiated Morgan Stanley Underweight $19
May-11-18Reiterated Needham Buy $33 → $30
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Jan-22-21 07:44PM  
01:10PM  
Jan-11-21 09:48AM  
Jan-10-21 04:00PM  
06:06AM  
Jan-09-21 05:51AM  
Jan-04-21 04:05PM  
Dec-31-20 06:05AM  
Dec-28-20 01:51AM  
Dec-23-20 06:06AM  
Dec-22-20 04:37PM  
10:39AM  
Dec-21-20 11:55AM  
07:30AM  
Dec-19-20 06:09AM  
Dec-16-20 08:00AM  
Dec-08-20 01:32PM  
Dec-07-20 08:00AM  
Dec-05-20 11:32AM  
Dec-02-20 08:00AM  
Nov-27-20 08:00AM  
05:51AM  
Nov-23-20 05:30PM  
Nov-11-20 08:24AM  
Nov-06-20 03:01PM  
10:33AM  
07:50AM  
Nov-05-20 08:30PM  
04:05PM  
03:45PM  
Nov-03-20 12:46PM  
06:32AM  
05:51AM  
Nov-02-20 04:05PM  
Oct-29-20 12:34PM  
Oct-28-20 06:57AM  
04:38AM  
Oct-27-20 08:24AM  
01:02AM  
Oct-26-20 08:00AM  
Oct-22-20 04:05PM  
Oct-20-20 10:57AM  
Oct-19-20 04:27PM  
06:59AM  
Oct-17-20 06:06AM  
Oct-13-20 09:12AM  
07:49AM  
Oct-09-20 03:02AM  
03:01AM  
Oct-07-20 07:21AM  
Oct-06-20 02:23PM  
Oct-03-20 06:55AM  
Oct-02-20 05:51AM  
Sep-21-20 10:20AM  
05:51AM  
Sep-19-20 12:30PM  
Sep-18-20 06:05PM  
Sep-15-20 08:00AM  
Sep-14-20 08:00AM  
Sep-13-20 06:52AM  
Sep-09-20 12:44PM  
Sep-08-20 11:57PM  
04:05PM  
11:41AM  
08:05AM  
08:01AM  
Sep-05-20 11:31AM  
Aug-25-20 10:02AM  
07:57AM  
Aug-24-20 08:00AM  
Aug-07-20 10:32AM  
Aug-06-20 08:20PM  
04:05PM  
Jul-30-20 12:33PM  
Jul-29-20 04:05PM  
Jul-23-20 12:20PM  
Jul-22-20 12:32PM  
11:40AM  
Jul-21-20 12:10PM  
10:00AM  
Jul-20-20 12:43PM  
08:00AM  
Jul-13-20 10:45AM  
Jul-10-20 07:16AM  
05:51AM  
Jul-03-20 12:36PM  
Jun-30-20 08:00AM  
Jun-22-20 11:02PM  
Jun-18-20 04:05PM  
Jun-17-20 01:42PM  
Jun-12-20 10:15AM  
Jun-11-20 08:00AM  
Jun-04-20 11:31AM  
Jun-03-20 04:05PM  
Jun-02-20 02:59AM  
May-28-20 06:58AM  
May-20-20 01:30PM  
May-13-20 05:00PM  
09:54AM  
May-06-20 04:05PM  
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, and other kinases implicated in growth and spread of cancer. It has collaboration and license agreement with Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., Roche, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Daiichi Sankyo Company, Limited, and clinical collaboration with Ipsen. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Senner Christopher J.EVP and CFOJan 12Option Exercise3.6630,000109,800275,596Jan 14 08:22 PM
Senner Christopher J.EVP and CFOJan 12Sale25.0030,000750,000245,596Jan 14 08:22 PM
Hessekiel JeffreyEVP and General CounselJan 04Option Exercise5.1250,000256,100541,754Jan 06 08:22 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 04Option Exercise1.7065,000110,500348,124Jan 06 08:40 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 04Sale20.3265,0001,320,800283,124Jan 06 08:40 PM
Lamb PeterEVP, Scientific Strategy & CSODec 18Option Exercise1.7065,000110,500348,124Dec 22 07:58 PM
Lamb PeterEVP, Scientific Strategy & CSODec 18Sale20.0165,0001,300,650283,124Dec 22 07:58 PM
WILLSEY LANCEDirectorDec 04Option Exercise5.82106,142617,746474,415Dec 04 07:56 PM
MARCHESI VINCENT TDirectorNov 24Option Exercise5.8240,004232,823130,216Nov 25 07:46 PM
MARCHESI VINCENT TDirectorNov 24Sale18.5040,004740,07490,212Nov 25 07:46 PM
Hessekiel JeffreyEVP and General CounselNov 15Option Exercise7.2730,000218,100494,254Nov 17 08:00 PM
WYSZOMIERSKI JACK LDirectorNov 10Option Exercise5.8262,403363,185231,809Nov 13 08:18 PM
WYSZOMIERSKI JACK LDirectorNov 10Sale20.6134,000700,740197,809Nov 13 08:18 PM
Hessekiel JeffreyEVP and General CounselOct 21Option Exercise7.2739,742288,924382,768Oct 23 08:08 PM
Hessekiel JeffreyEVP and General CounselOct 21Sale21.9539,742872,337343,026Oct 23 08:08 PM
Senner Christopher J.EVP and CFOOct 08Option Exercise3.6610,00036,600137,882Oct 09 08:04 PM
Senner Christopher J.EVP and CFOOct 08Sale25.0010,000250,000127,882Oct 09 08:04 PM
Hessekiel JeffreyEVP and General CounselSep 22Option Exercise7.2710,25874,576353,284Sep 24 08:03 PM
Hessekiel JeffreyEVP and General CounselSep 22Sale26.1410,258268,144343,026Sep 24 08:03 PM
Haley Patrick J.EVP, CommercialSep 21Option Exercise5.824,68027,238120,251Sep 23 08:12 PM
Haley Patrick J.EVP, CommercialSep 21Sale26.094,680122,101115,571Sep 23 08:12 PM
Hessekiel JeffreyEVP and General CounselSep 16Option Exercise7.2720,000145,400363,026Sep 16 08:24 PM
Hessekiel JeffreyEVP and General CounselSep 16Sale26.1120,000522,200343,026Sep 16 08:24 PM
Senner Christopher J.EVP and CFOSep 15Option Exercise3.6620,00073,200147,882Sep 15 08:03 PM
Senner Christopher J.EVP and CFOSep 15Sale25.0020,000500,000127,882Sep 15 08:03 PM
Hessekiel JeffreyEVP and General CounselSep 08Option Exercise5.18249,6921,293,315503,692Sep 10 08:39 PM
COHEN CHARLESDirectorSep 01Option Exercise5.82115,396671,605181,375Sep 03 08:05 PM
POSTE GEORGEDirectorAug 14Option Exercise5.8229,662172,633157,992Aug 14 07:50 PM
MORRISSEY MICHAELPresident and CEOJul 20Option Exercise6.21100,000621,000185,985Jul 22 07:06 PM
Haley Patrick J.EVP, CommercialJul 20Sale25.363,15179,909112,189Jul 22 07:01 PM
MORRISSEY MICHAELPresident and CEOJul 10Option Exercise6.21100,000621,000185,985Jul 10 08:48 PM
MORRISSEY MICHAELPresident and CEOJun 19Option Exercise6.21100,000621,000185,985Jun 19 09:20 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 08Option Exercise5.5126,000143,260152,531Jun 10 08:19 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 08Sale22.5626,000586,560126,531Jun 10 08:19 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJun 04Option Exercise1.70100,000170,000425,963Jun 05 08:00 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJun 04Sale22.96100,0002,296,000325,963Jun 05 08:00 PM
MORRISSEY MICHAELPresident and CEOMay 29Option Exercise6.21100,000621,000185,985May 29 09:36 PM
Garber Alan MDirectorMay 22Sale24.4236,111881,83112,718May 22 08:53 PM
MARCHESI VINCENT TDirectorMay 21Option Exercise5.8240,000232,800130,212May 22 09:11 PM
MARCHESI VINCENT TDirectorMay 21Sale24.6440,000985,60090,212May 22 09:11 PM
Haley Patrick J.EVP, CommercialMay 20Sale24.993,15178,743115,340May 22 08:17 PM
WILLSEY LANCEDirectorMay 18Option Exercise4.5830,000137,400398,273May 20 08:36 PM
WILLSEY LANCEDirectorMay 18Sale26.2630,000787,800368,273May 20 08:36 PM
SCANGOS GEORGE ADirectorMay 18Sale25.9675,0001,947,000714,717May 20 08:35 PM
SCANGOS GEORGE ADirectorMay 15Option Exercise5.1051,686263,613789,717May 15 08:31 PM
MORRISSEY MICHAELPresident and CEOMay 15Option Exercise6.21100,000621,000185,985May 15 09:29 PM
WILLSEY LANCEDirectorMay 14Option Exercise5.9215,00088,800383,273May 15 08:19 PM
WILLSEY LANCEDirectorMay 14Sale25.2615,000378,900368,273May 15 08:19 PM
Hessekiel JeffreyEVP and General CounselMay 13Option Exercise1.7025,00042,500264,188May 15 08:20 PM
PAPADOPOULOS STELIOSDirectorMay 13Option Exercise5.82120,791703,0041,173,359May 15 08:18 PM
Hessekiel JeffreyEVP and General CounselMay 11Option Exercise1.9038,00672,211277,194May 11 08:36 PM
MARCHESI VINCENT TDirectorMay 11Option Exercise4.5830,000137,400112,484May 13 09:16 PM
MARCHESI VINCENT TDirectorMay 11Sale26.3030,000789,00082,484May 13 09:16 PM
Hessekiel JeffreyEVP and General CounselMay 11Sale27.0938,0061,029,583239,188May 11 08:36 PM
Haley Patrick J.EVP, CommercialMay 08Option Exercise1.7621,37537,620139,866May 08 09:16 PM
PAPADOPOULOS STELIOSDirectorMay 08Option Exercise5.0345,000226,2001,097,568May 08 09:18 PM
Senner Christopher J.EVP and CFOMay 08Option Exercise3.6678,583287,614199,286May 08 09:22 PM
Hessekiel JeffreyEVP and General CounselMay 08Option Exercise1.9025,00047,500264,188May 11 08:36 PM
Hessekiel JeffreyEVP and General CounselMay 08Sale26.0425,000651,000239,188May 11 08:36 PM
Senner Christopher J.EVP and CFOMay 08Sale25.8178,5832,028,227120,703May 08 09:22 PM
PAPADOPOULOS STELIOSDirectorMay 08Sale25.8445,0001,162,8001,052,568May 08 09:18 PM
Haley Patrick J.EVP, CommercialMay 08Sale25.8721,375552,971118,491May 08 09:16 PM
Lamb PeterEVP, Scientific Strategy & CSOMay 07Option Exercise5.5150,000275,500176,531May 08 09:11 PM
POSTE GEORGEDirectorMay 07Option Exercise5.8230,000174,600142,792May 08 09:13 PM
FELDBAUM CARL BDirectorMay 07Option Exercise4.2731,546134,79840,067May 08 09:14 PM
Senner Christopher J.EVP and CFOMay 07Option Exercise3.6621,41778,386142,120May 08 09:22 PM
Hessekiel JeffreyEVP and General CounselMay 07Option Exercise1.9030,00057,000269,188May 11 08:36 PM
Hessekiel JeffreyEVP and General CounselMay 07Sale25.6130,000768,300239,188May 11 08:36 PM
Senner Christopher J.EVP and CFOMay 07Sale25.8021,417552,559120,703May 08 09:22 PM
FELDBAUM CARL BDirectorMay 07Sale25.0231,546789,2818,521May 08 09:14 PM
POSTE GEORGEDirectorMay 07Sale25.6130,000768,300112,792May 08 09:13 PM
Lamb PeterEVP, Scientific Strategy & CSOMay 07Sale25.5450,0001,277,000126,531May 08 09:11 PM
MORRISSEY MICHAELPresident and CEOMay 06Option Exercise1.70285,284484,983371,269May 08 09:10 PM
MORRISSEY MICHAELPresident and CEOApr 27Option Exercise1.70285,000484,500370,985Apr 29 08:10 PM
SCANGOS GEORGE ADirectorApr 24Sale26.2415,000393,600738,031Apr 24 08:24 PM
Haley Patrick J.EVP, CommercialApr 23Option Exercise1.705,0008,500121,873Apr 24 08:22 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 23Option Exercise1.70100,000170,000425,122Apr 24 08:25 PM
MORRISSEY MICHAELPresident and CEOApr 23Option Exercise5.51250,0001,377,500335,985Apr 24 08:41 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 23Sale26.00100,0002,600,000325,122Apr 24 08:25 PM
SCANGOS GEORGE ADirectorApr 23Sale25.99100,0002,598,635753,031Apr 24 08:24 PM
Haley Patrick J.EVP, CommercialApr 23Sale26.005,000130,000116,873Apr 24 08:22 PM
SCANGOS GEORGE ADirectorApr 22Sale25.054,200105,210853,031Apr 22 08:50 PM
MORRISSEY MICHAELPresident and CEOApr 21Option Exercise5.51220,0001,212,200393,064Apr 22 09:53 PM
SCANGOS GEORGE ADirectorApr 21Sale25.045,800145,232857,231Apr 22 08:50 PM
Haley Patrick J.EVP, CommercialApr 20Option Exercise1.705,0008,500121,873Apr 22 08:49 PM
MORRISSEY MICHAELPresident and CEOApr 20Option Exercise5.51240,0001,322,400325,985Apr 22 09:53 PM
SCANGOS GEORGE ADirectorApr 20Sale23.8950,0001,194,637863,031Apr 22 08:50 PM
Haley Patrick J.EVP, CommercialApr 20Sale24.005,000120,000116,873Apr 22 08:49 PM
SCANGOS GEORGE ADirectorApr 15Sale18.3125,000457,750913,031Apr 17 08:11 PM
SCANGOS GEORGE ADirectorApr 08Sale18.357,065129,643938,031Apr 09 08:20 PM
SCANGOS GEORGE ADirectorApr 07Sale18.2516,435299,939945,096Apr 09 08:20 PM
Lamb PeterEVP, Scientific Strategy & CSOApr 06Option Exercise5.5150,000275,500176,531Apr 08 08:12 PM
Lamb PeterEVP, Scientific Strategy & CSOApr 06Sale17.2650,000863,000126,531Apr 08 08:12 PM
WYSZOMIERSKI JACK LDirectorApr 03Option Exercise5.0345,000226,200175,526Apr 03 08:38 PM
WYSZOMIERSKI JACK LDirectorApr 03Sale16.5713,848229,461161,678Apr 03 08:38 PM
SCANGOS GEORGE ADirectorMar 31Sale18.061,50027,090961,531Apr 02 08:08 PM
Haley Patrick J.EVP, CommercialMar 20Sale15.374,31866,368116,873Mar 20 09:03 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMar 04Option Exercise1.70100,000170,000425,122Mar 06 08:01 PM
MORRISSEY MICHAELPresident and CEOMar 04Option Exercise5.5150,000275,500135,985Mar 06 08:07 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMar 04Sale19.40100,0001,940,000325,122Mar 06 08:01 PM